Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy

References

• Strzelczyk A, Reese JP, Dodel R, et al. Cost of epilepsy - a systematic review. Pharmacoeconomics. 2008;26(6):463–476.
   PubMed Web of Science ®Google Scholar
• Begley CE, Durgin TL. The direct cost of epilepsy in the United States: a systematic review of estimates. Epilepsia. 2015;56(9):1376–1387.
   PubMed Web of Science ®Google Scholar
• Frost FJ, Hurley JS, Petersen HV, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia. 2000;41(8):1020–1026.
   PubMed Web of Science ®Google Scholar
• Jennum P, Christensen J, Ibsen R, et al. Long-term socioeconomic consequences and health care costs of childhood and adolescent-onset epilepsy. Epilepsia. 2016;57(7):1078–1085.
   PubMed Web of Science ®Google Scholar
• De Kinderen RJA, Evers SMAA, Rinkens R, et al. Side-effects of antiepileptic drugs: the economic burden. Seizure. 2014;23(3):184–190.
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia. 2007;48(12):2224–2233.
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC. Comorbidity between neurological illness and psychiatric disorders. CNS Spectrums. 2016;21(3):230–238.
   PubMed Web of Science ®Google Scholar
• Collings JA. Psychosocial well-being and epilepsy: an empirical study. Epilepsia. 1990;31(4):418–426.
   PubMed Web of Science ®Google Scholar
• Baker GA, Brooks J, Buck D, et al. The stigma of epilepsy: a European perspective. Epilepsia. 2000;41(1):98–104.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Abajobir AA, Abate KH, et al. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–897.
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(14):1172–1177.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339–1341.
   PubMed Web of Science ®Google Scholar
• Langfitt JT. Cost evaluations in epilepsy: an update. Epilepsia. 2000;41:S62–S68.
   PubMed Web of Science ®Google Scholar
• Wijnen BFM, Van Mastrigt GAPG, Evers SMAA, et al. A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia. 2017;58(5):706–726.
   PubMed Web of Science ®Google Scholar
• Bolin K, Forsgren L. The cost effectiveness of newer epilepsy treatments. PharmacoEconomics. 2012;30(10):903–923.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–283.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12(Suppl 1):S5–S9.
   PubMed Web of Science ®Google Scholar
• Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41:S42–S52.
   PubMed Web of Science ®Google Scholar
• Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand. 2005;112:30–35.
   Web of Science ®Google Scholar
• Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs (vol 11, pg 792, 2012). Lancet Neurol. 2012;11(9):746.
   Web of Science ®Google Scholar
• Levy P. Economic evaluation of antiepileptic drug therapy: a methodologic review. Epilepsia. 2002;43(5):550–558.
   PubMed Web of Science ®Google Scholar
• Pillas MD, Selai C. Economic aspects of epilepsy and antiepileptic treatment: a review of the literature. Expert Rev Pharmacoeconomics Outcomes Res. 2005;5(3):327–338.
   PubMedGoogle Scholar
• Heaney Dominic C, Begley Charles E. Economic evaluation of epilepsy treatment: a review of the literature. Epilepsia. 2002;43:10–16.
   PubMed Web of Science ®Google Scholar
• O’Neill BA, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure. 1995;4(1):37–44.
   PubMedGoogle Scholar
• Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: a systematic review. BMC Neurology. 2015;15(1):245.
   PubMedGoogle Scholar
• Simoens S. Lacosamide as adjunctive therapy for partial-onset epileptic seizures: a review of the clinical and economic literature. Curr Med Res Opin. 2011;27(7):1329–1338.
   PubMed Web of Science ®Google Scholar
• Beghi E, Atzeni L, Garattini L. Economic analysis of newer antiepileptic drugs. CNS Drugs. 2008;22(10):861–875.
   PubMed Web of Science ®Google Scholar
• Wilby J, Kainth A, Hawkins N, et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess. 2005;9(15).
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Talati R, Scholle JM, Phung OJ et al. Effectiveness and safety of antiepileptic medications in patients with epilepsy. Comparative Effectiveness Review No. 40. (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 20-2007-10067-I.). (AHRQ Publication No. 11 (12)-EHC082-EF, Rockville, MD, Agency for Healthcare Research and Quality. December 2011. Available from www.effectivehealthcare.ahrq.gov/reports/final.cfm)
   Google Scholar
• Theodore WH, Spencer SS, Wiebe S, et al. Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia. 2006;47(10):1700–1722.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Nair DR. The effects of antiepileptic drugs on vascular risk factors: a narrative review. Seizure. 2014;23(9):677–684.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Nune G, Roberts SE, et al. The Personal Impact of Epilepsy Scale (PIES). Epilepsy Behav. 2015;42(Supplement C):140–146.
   PubMedGoogle Scholar
• Balabanov PP, Zahariev ZI. A pharmacoeconomic comparison of monotherapy with Tegretol, Finlepsin and Trileptal (preliminary data). Folia Med (Plovdiv). 2006;48(2):37–43.
   PubMedGoogle Scholar
• Balabanov PP, Zahariev ZI, Mateva NG. Evaluation of the factors affecting the quality of life and total costs in epilepsy patients on monotherapy with carbamazepine and valproate. Folia Med (Plovdiv). 2008;50(2):18–23.
   PubMedGoogle Scholar
• Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand. 2010;121(6):406–412.
   PubMed Web of Science ®Google Scholar
• Clements KM, Skornicki M, O’Sullivan AK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav. 2013;29(1):184–189.
   PubMed Web of Science ®Google Scholar
• Hawkins N, Epstein D, Drummond M, et al. Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making. 2005;25(5):493–510.
   PubMed Web of Science ®Google Scholar
• Jentink J, Boersma C, De Jong-Van Den Berg LT, et al. Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. J Med Econ. 2012;15(5):862–868.
   PubMedGoogle Scholar
• Knoester PD, Deckers CL, Termeer EH, et al. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients. Value Health. 2007;10(3):173–182.
   PubMed Web of Science ®Google Scholar
• Bolin K, Wachtmeister K, Stefan F, et al. Retigabine as add-on treatment of refractory epilepsy–a cost-utility study in a Swedish setting. Acta Neurol Scand. 2013;127(6):419–426.
   PubMed Web of Science ®Google Scholar
• Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy: cost-effectiveness in refractory epilepsy. Clin Drug Investig. 2003;23(4):225–232.
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol. 1998;53(6):421–427.
   PubMed Web of Science ®Google Scholar
• Remak E, Hutton J, Price M, et al. Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate. Eur J Health Econ. 2003;4(4):271–278.
   PubMedGoogle Scholar
• Remák E, Hutton J, Selai CE, et al. A cost-utility analysis of adjunctive treatment with newer antiepileptic drugs in the UK. J Med Econ. 2004;7(1–4):29–40.
   Google Scholar
• Simoens S, De Naeyer L, Dedeken P. Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium. CNS Drugs. 2012;26(4):337–350.
   PubMed Web of Science ®Google Scholar
• Spackman DE, Yeates A, Rentz AM, et al. The cost effectiveness of zonisamide as adjunctive therapy in adult partial seizure epilepsy. J Med Econ. 2007;10(4):455–473.
   Google Scholar
• Suh GH, Lee SK. Economic evaluation of add-on levetiracetam for the treatment of refractory partial epilepsy in Korea. Psychiatry Investig. 2009;6(3):185–193.
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia. 2008;49(3):431–437.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal 2013. (NICE (National Institute for Health and Care Excellence), 2013)
   Google Scholar
• Selai CE, Trimble MR. Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value? Seizure. 1998;7(5):417–418.
   PubMed Web of Science ®Google Scholar
• Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure. 1999;8(1):8–13.
   PubMed Web of Science ®Google Scholar
• Selai C, Kaiser S, Trimble M, et al. PNP15 Evaluation of the relationship between epilepsy severity and utility. Value Health. 2002;5(6):512–513.
   Web of Science ®Google Scholar
• Selai C, Trimble M, Kaiser S, et al. P330 New antiepileptic drugs: clinical outcome and utility scores. Epilepsia. 2002;43(S8):65–207.
   PubMedGoogle Scholar
• Selai CE, Trimble MR, Price MJ, et al. Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Curr Med Res Opin. 2005;21(5):733–739.
   PubMed Web of Science ®Google Scholar
• Rabin R, Charro FD. EQ-SD: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–343.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Brandenburg NA, Xu X, et al. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav. 2007;11(2):179–184.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 1998;39(1):81–88.
   PubMed Web of Science ®Google Scholar
• Verdian L, Oyee Y, Heyes A, et al. Eliciting preferences for health states associated with Lennox-Gastaut syndrome (LGS). In: American Epilepsy Society 62nd Annual Meeting. (Seattle, Washington, 2008)
   Google Scholar
• Kavitha S, Anbuchelvan T, Mahalakshmi V, et al. Stevens–Johnson syndrome induced by a combination of lamotrigine and valproic acid. J Pharm Bioallied Sci. 2015;7(Suppl 2):S756–S758.
   PubMedGoogle Scholar
• Arif H, Buchsbaum R, Weintraub D, et al. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14(1):202–209.
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76(Supplement C):24–31.
   PubMedGoogle Scholar
• Weintraub D, Buchsbaum R, Resor SR, et al. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007;10(1):105–110.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 2017.
   Google Scholar
• Pharmacoeconomic guidelines around the world: Country-specific pharmacoeconomic guidelines. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). cited Dec 15, 2017 Available from: https://www.ispor.org/PEguidelines/index.asp
   Google Scholar
• Cleemput I, Neyt M, Van De Sande S, et al. Belgian guidelines for economic evaluations and budget impact analyses. second ed. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre(KCE; 2012.
   Google Scholar
• Ivanova JI, Birnbaum HG, Kidolezi Y, et al. Economic burden of epilepsy among the privately insured in the US. PharmacoEconomics. 2010;28(8):675–685.
   PubMed Web of Science ®Google Scholar
• Wijnen BFM, Mosweu I, Majoie MHJM, et al. A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur JHealth Econ. 2017.
   Google Scholar
• Tharayil JJ, Chiang S, Moss R, et al. A big data approach to the development of mixed-effects models for seizure count data. Epilepsia. 2017;58(5):835–844.
   PubMed Web of Science ®Google Scholar
• Ahn JE, Plan EL, Karlsson MO, et al. Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment. J Clin Pharmacol. 2012;52(6):880–892.
   PubMed Web of Science ®Google Scholar
• Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;(11).
   Web of Science ®Google Scholar
• Berm EJ, Looff M, Wilffert B, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PloS One. 2016;11(1):e0146262.
   PubMed Web of Science ®Google Scholar
• Steel D, Symonds JD, Zuberi SM, et al. Dravet syndrome and its mimics: beyond SCN1A. Epilepsia. 2017;58(11):1807–1816.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Ann Sakowski J, Trosman J, et al. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014;16(3):251–257.
   PubMed Web of Science ®Google Scholar
• Poduri A, Sheidley BR, Shostak S, et al. Genetic testing in the epilepsies—developments and dilemmas. Nat Rev Neurol. 2014;10:293–299.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 2016;86(12):1086–1094.
   PubMed Web of Science ®Google Scholar
• Deng C, Plan EL, Karlsson MO. Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations. J Pharmacokinet Pharmacodyn. 2016;43(3):305–314.
   PubMed Web of Science ®Google Scholar